Descripción del uso de levetiracetam para el tratamiento de síndromes convulsivos y epilepsia en el hospital clínico Herminda Martín de Chillán entre los años 2014-2018.
Keywords:
epilepsia, levetiracetam, anticonvulsivanteAbstract
: Epilepsy is a common and far-reaching neurological condition (2). The clinical manifestations are epileptic seizures, which can be controlled by using the correct anticonvulsant medication. One of these drugs is levetiracetam (LEV), which is included as a pharmacological treatment for epilepsy in the epilepsy program in Chile. In this context, it is relevant to fully define and establish the profile of adverse effects. To do this, a retrospective descriptive study was carried out whose population corresponds to the patients treated in the outpatient clinic of specialties of the Hospital Clínico Herminda Martín, of the Ñuble health service, between January 2014 and August 2018, over 18 years of age, with a diagnosis of convulsive syndrome and / or epilepsy, found with drug treatment for their disease. The results showed that 21.2% (n = 38) were treated with LEV. Among all the adverse effects recorded for this drug, 40.0% correspond to irritability, 20.0% to mood disorders and 20.0% to persistent seizures. In conclusion, despite the good level of tolerance shown by this drug, there are several adverse effects with a direct impact on the quality of life of the patient that require further studies.
References
World Health Organization–International. League against Epilepsy – International Bureau for Epilepsy. Atlas: Epilepsy Care in the World [Internet]. Ginebra, (Suiza) WHO.NICE. National Institute for Clinical Excellence; 2005 [consultado el 21 de noviembre del 2018] Disponible en: https://www.who.int/mental_health/neurology/Epilepsy_atlas_r1.pdf
NICE Clinical Guideline 137. Epilepsies: diagnosis and management of the epilepsies in adults and children in primary and secondary care [Internet]. Inglaterra. National Institute for Health and Care Excellence; 2012. Disponible en: www.guidance.nice.org.uk/CG137 [consultado el 15 de noviembre del 2018].
Organización Mundial de la Salud. Trastornos neurológicos: desafíos para la salud pública [Internet]. Ginebra, Suiza: OMS; 2006 [consultado el 21 de noviembre del 2018]. Disponible en: http://new.paho.org/hq/dmdocuments/2008/Trastornos_Neurologicos.pdf.
Deshpande LS, DeLorenzo RJ. [Mechanisms of levetiracetam in the control of status epilepticus and epilepsy]. Front Neurol. 5:11 2014. [consultado el 16 de noviembre del 2018] Disponible en: https://www.frontiersin.org/articles/10.3389/fneur.2014.00011/full
MINSAL. Programa de Epilepsia en Chile. Orientaciones técnicas. Consultoría en salud mental. [Internet] Santiago: MINSAL; 2016 [consultado el 21 de noviembre del 2018]. Disponible en: http://www.redcronicas.cl/wrdprss_minsal/wp-content/uploads/2014/04/PROGRAMA-DE-EPILEPSIA-EN-CHILE-2016.pdf
Sirsi D, Safdieh JE. The safety of levetiracetam. [Internet] Expert Opin Drug Saf 2007;6(3):241–50. [consultado el 15 de noviembre del 2018] Disponible en: https://www.tandfonline.com/doi/abs/10.1517/14740338.6.3.241
Perucca P, Gilliam FG Adverse effects of antiepileptic drugs. [Internet] Lancet Neurol 2012;11:792–802. [consultado el 15 de noviembre del 2018] Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1474442212701539
Briggs DE, French JA. Levetiracetam safety profiles and tolerability in epilepsy patients. [Internet] Expert Opin Drug Saf 2004;3(5):415–24. [consultado el 16 de noviembre del 2018] Disponible en: https://www.tandfonline.com/doi/abs/10.1517/14740338.3.5.415
French J, Edrich P, Cramer JA. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. [Internet] Epilepsy Res [Comparative Study Research Support, Non-U.S. Gov’t Review]. 2001;47(1–2):77–90. [consultado el 16 de noviembre del 2018] Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0920121101002960
Zheng, F., Du, C., & Wang, X. Levetiracetam for the treatment of status epilepticus. [Internet] Expert review of neurotherapeutics – 2015; 15(10), 1113-1121. [consultado el 16 de noviembre del 2018] Disponible en: https://www.tandfonline.com/doi/abs/10.1586/14737175.2015.1088785
Nevitt SJ, Sudell M, Weston J, Tudur Smith C, Marson AG. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.[Internet] Cochrane Database of Systematic Reviews 2017, Issue 6. Art. No.: CD011412. [consultado el 16 de noviembre del 2018] Disponible en: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011412.pub2/abstract
Mbizvo GK, Dixon P, Hutton JL, Marson AG Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review. [Internet] Cochrane database Syst Rev 9:CD001901. [consultado el 16 de noviembre del 2018] Disponible en: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001901.pub2/abstract/es
Verrotti A, Prezioso G, Di Sabatino F, Franco V, Chiarelli F, Zaccara G. The adverse event profile of levetiracetam: A meta-analysis on children and adults. [Internet] Seizure. 2015;31:49-55. [consultado el 21 de noviembre del 2018] Disponible en: https://www.sciencedirect.com/science/article/pii/S1059131115001673
Cramer, J. A., De Rue, K., Devinsky, O., Edrich, P., & Trimble, M. R. (2003). A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. [Internet] Epilepsy & Behavior, 4(2), 124-132. [consultado el 17 de noviembre del 2018] Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1525505003000052
Gambardella, A., Labate, A., Colosimo, E., Ambrosio, R., & Quattrone, A. Monotherapy for partial epilepsy: focus on levetiracetam. [Internet] Neuropsychiatric disease and treatment 2008; 4(1), 33. [consultado el 17 de noviembre del 2018] Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515905/
Weintraub D, Buchsbaum R, Resor SR Jr, Hirsch LJ. Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. [Internet] Epilepsy behavior 2007; 10(1):105-10 [consultado el 16 de noviembre del 2018] Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1525505006003246
Wood, H. Epilepsy: psychiatric adverse effects of levetiracetam linked to genetic variation in dopamine signalling. [Internet] Nat Rev Neurol. 2012; 8: 532 [consultado el 16 de noviembre del 2018] Disponible en: https://www.nature.com/articles/nrneurol.2012.184
Kang, B.S., Moon, H.J., Kim, Y.-S., Lee, S.-T., Jung, K.-H., Chu, K. et al. The long-term efficacy and safety of levetiracetam in a tertiary epilepsy centre. [Internet] Epileptic Disord. 2013; 15: 302–310 [consultado el 17 de noviembre del 2018] Disponible en: https://link.springer.com/article/10.1684/epd.2013.0599
Zlott, D.A. and Byrne, M. Mechanisms by which pharmacologic agents ay contribute to fatigue.[Internet] PM R. 2010; 2: 451–455 [consultado el 21 de noviembre del 2018] Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1934148210003382
Chung, S., Ceja, H., Gawłowicz, J., McShea, C., Schiemann, J., & Lu, S. Levetiracetam extended release for the treatment of patients with partial-onset seizures: a long-term, open-label follow-up study. [Internet] Epilepsy research, 2016;120, 7-12. [consultado el 16 de noviembre del 2018] Disponible en: https://pubmed.ncbi.nlm.nih.gov/22516508/
Downloads
Published
Versions
- 2022-04-04 (2)
- 2022-04-03 (1)
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Héctor Alejandro Zagal Acuña
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
